These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 37675397)
1. Outcomes of MIS-C patients treated with anakinra: a retrospective multicenter national study. Licciardi F; Covizzi C; Dellepiane M; Olivini N; Mastrolia MV; Lo Vecchio A; Monno V; Tardi M; Mauro A; Alessio M; Filocamo G; Cattalini M; Taddio A; Caorsi R; Marseglia GL; La Torre F; Campana A; Simonini G; Ravelli A; Montin D Front Pediatr; 2023; 11():1137051. PubMed ID: 37675397 [TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes and safety of anakinra in the treatment of multisystem inflammatory syndrome in children: a single center observational study. Dizon BLP; Redmond C; Gotschlich EC; Sule S; Ronis T; Vazzana KM; Sherman MA; Connor R; Bosk A; Dham N; Harahsheh AS; Wells E; DeBiasi R; Srinivasalu H Pediatr Rheumatol Online J; 2023 Jul; 21(1):76. PubMed ID: 37525200 [TBL] [Abstract][Full Text] [Related]
3. Impact of anakinra use on clinical outcomes in children with moderate or severe multisystem inflammatory syndrome in children: a propensity score matched retrospective cohort study. Akkoyun EB; Most Z; Katragadda H; Yu A; Nassi L; Oakman N; Ginsburg S; Maamari M Pediatr Rheumatol Online J; 2023 Nov; 21(1):141. PubMed ID: 37996856 [TBL] [Abstract][Full Text] [Related]
4. Anakinra treatment in multisystemic inflammatory syndrome in children (MIS-C) associated with COVID-19. Çaǧlayan Ş; Sönmez HE; Otar Yener G; Baǧlan E; Öztürk K; Ulu K; Guliyeva V; Demirkol D; Çakan M; Özdel S; Bukulmez H; Aktay Ayaz N; Sözeri B Front Pediatr; 2022; 10():942455. PubMed ID: 36061383 [TBL] [Abstract][Full Text] [Related]
5. Subcutaneous anakinra in the management of refractory MIS-C in France. Dusser P; Belot A; Bajolle F; Kevorkian-Verguet C; Meinzer U; Huet F; Tiriau S; Kone-Paut I Front Pediatr; 2024; 12():1270878. PubMed ID: 38464895 [TBL] [Abstract][Full Text] [Related]
6. Variation in Early Anakinra Use and Short-Term Outcomes in Multisystem Inflammatory Syndrome in Children. Chang JC; Young CC; Muscal E; Sexson Tejtel SK; Newhams MM; Kucukak S; Crandall H; Maddux AB; Rowan CM; Halasa NB; Harvey HA; Hobbs CV; Hall MW; Kong M; Aguiar CL; Schuster JE; Fitzgerald JC; Singh AR; Wellnitz K; Nofziger RA; Cvijanovich NZ; Mack EH; Schwarz AJ; Heidemann SM; Newburger JW; Zambrano LD; Campbell AP; Patel MM; Randolph AG; Son MBF; Arthritis Rheumatol; 2023 Aug; 75(8):1466-1476. PubMed ID: 36908050 [TBL] [Abstract][Full Text] [Related]
7. Early combination therapy with immunoglobulin and steroids is associated with shorter ICU length of stay in Multisystem Inflammatory Syndrome in Children (MIS-C) associated with COVID-19: A retrospective cohort analysis from 28 U.S. Hospitals. Harthan AA; Nadiger M; McGarvey JS; Hanson K; Gharpure VP; Bjornstad EC; Chiotos K; Miller AS; Reikoff RA; Gajic O; Kumar V; Walkey AJ; Kashyap R; Tripathi S; Pharmacotherapy; 2022 Jul; 42(7):529-539. PubMed ID: 35661394 [TBL] [Abstract][Full Text] [Related]
8. Early anakinra treatment improves cardiac outcome of multisystem inflammatory syndrome in children, regardless of disease severity. Taddio A; Della Paolera S; Abbagnato L; Agrusti A; Badolato R; Biscaro F; Caorsi R; Consolaro A; Dellepiane RM; Fabi M; Floretta I; Gattorno M; Giangreco M; La Torre F; Maggio MC; Mambelli L; Mauro A; Mastrolia MV; Meneghel A; Montin D; Ricci F; Simonini G; Smarrazzo A; Sottile R; Stucchi S; Tardi M; Verdoni L; Zuccotti G; Zunica F; Ravelli A; Cattalini M; Rheumatology (Oxford); 2024 Feb; 63(2):366-375. PubMed ID: 37647645 [TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of pharmacological approaches available for multisystem inflammatory syndrome in children (MIS-C): a systematic review. Velusamy Y; Vivekanandan G; Romli MH; Shankar A; Karuppiah T; Yubbu P Turk J Pediatr; 2023; 65(5):719-738. PubMed ID: 37853964 [TBL] [Abstract][Full Text] [Related]
10. Case Report: Case Series of Children With Multisystem Inflammatory Syndrome Following SARS-CoV-2 Infection in Switzerland. Fouriki A; Fougère Y; De Camaret C; Blanchard Rohner G; Grazioli S; Wagner N; Relly C; Pachlopnik Schmid J; Trück J; Kottanatu L; Perez E; Perez MH; Schaffner D; Asner SA; Hofer M Front Pediatr; 2020; 8():594127. PubMed ID: 33469522 [TBL] [Abstract][Full Text] [Related]
11. Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with COVID-19: A Case Series Experience in a Tertiary Care Hospital of Southern Turkey. Tolunay O; Çelik Ü; Arslan İ; Orgun A; Demir H; Demir O; Dağdelen EÇ J Trop Pediatr; 2021 May; 67(2):. PubMed ID: 34028528 [TBL] [Abstract][Full Text] [Related]
12. Case Report: Use of Anakinra in Multisystem Inflammatory Syndrome During COVID-19 Pandemic. Della Paolera S; Valencic E; Piscianz E; Moressa V; Tommasini A; Sagredini R; Kiren V; Comar M; Taddio A Front Pediatr; 2020; 8():624248. PubMed ID: 33708752 [TBL] [Abstract][Full Text] [Related]
13. Association of Intravenous Immunoglobulins Plus Methylprednisolone vs Immunoglobulins Alone With Course of Fever in Multisystem Inflammatory Syndrome in Children. Ouldali N; Toubiana J; Antona D; Javouhey E; Madhi F; Lorrot M; Léger PL; Galeotti C; Claude C; Wiedemann A; Lachaume N; Ovaert C; Dumortier M; Kahn JE; Mandelcwajg A; Percheron L; Biot B; Bordet J; Girardin ML; Yang DD; Grimaud M; Oualha M; Allali S; Bajolle F; Beyler C; Meinzer U; Levy M; Paulet AM; Levy C; Cohen R; Belot A; Angoulvant F; JAMA; 2021 Mar; 325(9):855-864. PubMed ID: 33523115 [TBL] [Abstract][Full Text] [Related]